Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosfomycin tromethamine

Drug Profile

Fosfomycin tromethamine

Alternative Names: Fosfomycin trometamol; FZ 588; Monofoscin; Monuril; Urizone; Z 1282

Latest Information Update: 13 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zambon Group SpA
  • Developer AbbVie; Adcock Ingram Pharmaceuticals; Inpharzam Ricerche S.A.; Mayne Pharma Group; Orion; Rontag; Roux Ocefa; Zambon Company SpA
  • Class Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Urinary tract infections

Most Recent Events

  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 25 Sep 2017 Launched for Urinary tract infections in Turkey, Mexico, Indonesia, Taiwan, Philippines, Malaysia, Lebanon, Hong Kong, China, Thailand, Israel, Peru, Tunisia, Slovenia, Russia (PO)
  • 15 Sep 2017 Fosfomycin tromethamine licensed to Mayne Pharma Group in Australia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top